TAK-280

TAK-280 is an investigational bi-specific monoclonal antibody developed using the COBRA (Conditional Bispecific Redirected Activation) platform. It is designed as a conditionally active T-cell engager that targets B7 homolog 3 protein (B7-H3, also known as CD276), which is highly expressed in a variety of solid tumors including metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer, head and neck squamous cell carcinoma, bladder cancer, small-cell lung cancer, cutaneous melanoma, and metastatic uveal melanoma. In its prodrug form, TAK-280 binds to B7-H3 but not to CD3ε. Upon exposure to the protease-rich tumor microenvironment (TME), it undergoes protease-mediated activation resulting in formation of active dimers capable of binding both B7-H3 on tumor cells and CD3 on T-cells. This conditional activation leads to localized T-cell engagement and cytotoxic antitumor response while limiting toxicity to normal tissues. The drug is administered intravenously and remains under clinical investigation for unresectable locally advanced or metastatic cancers.

Other names

TAK-280TAK280TAK 280MVC-280MVC280MVC 280